These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38510282)

  • 21. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
    Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
    JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
    Nassar AH; El Zarif T; Khalid AB; Rahme S; Zhong C; Kwak L; Salame M; Farhat EB; Freeman D; El-Am E; Ravishankar A; Ahmad B; Nana FA; Kaldas D; Naqash AR; Sharon E; LeBoeuf NR; Cortellini A; Malgeri A; Gupta S; Al-Hader A; Sparks JA; Linnoila J; Hamnvik OR; Mouhieddine TH; Marron T; Parikh K; McKay RR; Dilling T; Choueiri TK; Adib E; Najem E; Kim SY; Sonpavde G
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38448038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
    Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
    Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors.
    Lyu J; Yang N; Xiao L; Nie X; Xiong J; Liu Y; Zhang M; Zhang H; Tang C; Pan S; Liang L; Bai H; Li C; Kuang H; Li T
    Front Nutr; 2023; 10():1113875. PubMed ID: 36969820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
    You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
    Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer.
    Peravali M; Ahn J; Chen K; Rao S; Veytsman I; Liu SV; Kim C
    Oncologist; 2021 Aug; 26(8):694-700. PubMed ID: 33844354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ning C; Zhang X; Wang Y; Yang X; Yang X; Chao J; Xun Z; Xue J; Wang Y; Sun H; Li Y; Zhang N; Zhu C; Hou X; Sang X; Zhao H
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1461-1471. PubMed ID: 37433375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
    Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT; Goldman JM; Nazha B; Carthon BC; Harris WB; Kucuk O; Master VA; Bilen MA
    J Immunother Precis Oncol; 2022 Aug; 5(3):52-57. PubMed ID: 36034580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma.
    Zhao XH; Gao HM; Wen JY; Wang HS; Wu LY; Song CY; Deng WZ; Zhu SC; Shen WB
    Discov Oncol; 2023 Sep; 14(1):165. PubMed ID: 37665394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.
    Bishop AJ; Amini B; Lin H; Raza SM; Patel S; Grosshans DR; Ghia A; Farooqi A; Guadagnolo BA; Mitra D; Akdemir KC; Lazar AJ; Wang WL; Alvarez-Breckenridge C; Bird J; Rhines LD; Somaiah N; Conley AP
    J Immunother; 2022 Oct; 45(8):374-378. PubMed ID: 35943386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
    Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
    Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    Tsukita Y; Tozuka T; Kushiro K; Hosokawa S; Sumi T; Uematsu M; Honjo O; Yamaguchi O; Asao T; Sugisaka J; Saito G; Shiihara J; Morita R; Katakura S; Yasuda T; Hisakane K; Miyauchi E; Morita S; Kobayashi K; Asahina H
    JAMA Oncol; 2024 Apr; 10(4):439-447. PubMed ID: 38451530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
    El Zarif T; Nassar AH; Pond GR; Zhuang TZ; Master V; Nazha B; Niglio S; Simon N; Hahn AW; Pettaway CA; Tu SM; Abdel-Wahab N; Velev M; Flippot R; Buti S; Maruzzo M; Mittra A; Gheeya J; Yang Y; Rodriguez PA; Castellano D; de Velasco G; Roviello G; Antonuzzo L; McKay RR; Vincenzi B; Cortellini A; Hui G; Drakaki A; Glover M; Khaki AR; El-Am E; Adra N; Mouhieddine TH; Patel V; Piedra A; Gernone A; Davis NB; Matthews H; Harrison MR; Kanesvaran R; Giudice GC; Barata P; Farolfi A; Lee JL; Milowsky MI; Stahlfeld C; Appleman L; Kim JW; Freeman D; Choueiri TK; Spiess PE; Necchi A; Apolo AB; Sonpavde GP
    J Natl Cancer Inst; 2023 Dec; 115(12):1605-1615. PubMed ID: 37563779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.